Berenberg has revised its price target and earnings estimates for Galderma following the company's record first-half 2026 results, citing strength in the integrated model that combines injectables, skincare, and devices. The analyst's upgrade reflects confidence in Galderma's ability to cross-sell across product categories and geographies.